Tags

Type your tag names separated by a space and hit enter

Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects.
Arthritis Care Res (Hoboken). 2012 Feb; 64(2):269-72.AC

Abstract

OBJECTIVE

Statins, among the most commonly prescribed medications, are associated with a wide range of musculoskeletal side effects. These include a progressive autoimmune myopathy with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies that requires immunosuppression. However, it remains unknown whether these antibodies are found in statin users with and without self-limited musculoskeletal side effects; this limits their diagnostic utility. The current work assessed the prevalence of anti-HMGCR antibodies in these groups of statin users.

METHODS

We determined the prevalence of anti-HMGCR antibodies in 1,966 participants (including 763 current statin users) in a substudy of the community-based Atherosclerosis Risk in Communities (ARIC) Study and 98 French Canadian subjects with familial hypercholesterolemia, including 51 with documented statin intolerance.

RESULTS

No participant in the ARIC substudy, including those with past or current statin exposure at the time of sample collection, had anti-HMGCR antibodies. Similarly, none of 51 patients with self-limited statin intolerance or 47 statin-tolerant patients receiving maximal statin therapy were anti-HMGCR positive.

CONCLUSION

The majority of patients with and without statin exposure, including those with self-limited statin intolerance, do not develop anti-HMGCR antibodies. Therefore, anti-HMGCR antibodies are highly specific for those with an autoimmune myopathy.

Authors+Show Affiliations

Johns Hopkins University, Baltimore, Maryland, USA. amammen@jhmi.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21972203

Citation

Mammen, Andrew L., et al. "Rarity of Anti-3-hydroxy-3-methylglutaryl-coenzyme a Reductase Antibodies in Statin Users, Including Those With Self-limited Musculoskeletal Side Effects." Arthritis Care & Research, vol. 64, no. 2, 2012, pp. 269-72.
Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken). 2012;64(2):269-72.
Mammen, A. L., Pak, K., Williams, E. K., Brisson, D., Coresh, J., Selvin, E., & Gaudet, D. (2012). Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care & Research, 64(2), 269-72. https://doi.org/10.1002/acr.20662
Mammen AL, et al. Rarity of Anti-3-hydroxy-3-methylglutaryl-coenzyme a Reductase Antibodies in Statin Users, Including Those With Self-limited Musculoskeletal Side Effects. Arthritis Care Res (Hoboken). 2012;64(2):269-72. PubMed PMID: 21972203.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. AU - Mammen,Andrew L, AU - Pak,Katherine, AU - Williams,Emma K, AU - Brisson,Diane, AU - Coresh,Joe, AU - Selvin,Elizabeth, AU - Gaudet,Daniel, PY - 2011/10/6/entrez PY - 2011/10/6/pubmed PY - 2012/3/14/medline SP - 269 EP - 72 JF - Arthritis care & research JO - Arthritis Care Res (Hoboken) VL - 64 IS - 2 N2 - OBJECTIVE: Statins, among the most commonly prescribed medications, are associated with a wide range of musculoskeletal side effects. These include a progressive autoimmune myopathy with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies that requires immunosuppression. However, it remains unknown whether these antibodies are found in statin users with and without self-limited musculoskeletal side effects; this limits their diagnostic utility. The current work assessed the prevalence of anti-HMGCR antibodies in these groups of statin users. METHODS: We determined the prevalence of anti-HMGCR antibodies in 1,966 participants (including 763 current statin users) in a substudy of the community-based Atherosclerosis Risk in Communities (ARIC) Study and 98 French Canadian subjects with familial hypercholesterolemia, including 51 with documented statin intolerance. RESULTS: No participant in the ARIC substudy, including those with past or current statin exposure at the time of sample collection, had anti-HMGCR antibodies. Similarly, none of 51 patients with self-limited statin intolerance or 47 statin-tolerant patients receiving maximal statin therapy were anti-HMGCR positive. CONCLUSION: The majority of patients with and without statin exposure, including those with self-limited statin intolerance, do not develop anti-HMGCR antibodies. Therefore, anti-HMGCR antibodies are highly specific for those with an autoimmune myopathy. SN - 2151-4658 UR - https://www.unboundmedicine.com/medline/citation/21972203/Rarity_of_anti_3_hydroxy_3_methylglutaryl_coenzyme_A_reductase_antibodies_in_statin_users_including_those_with_self_limited_musculoskeletal_side_effects_ L2 - https://doi.org/10.1002/acr.20662 DB - PRIME DP - Unbound Medicine ER -